Retrospective Analysis of CT-based Habitat Analysis for Predicting pCR and Survival of ESCC Treated by Neoadjuvant Chemoradiotherapy and Esophagectomy

回顾性分析基于CT的食管癌组织形态分析在预测新辅助放化疗联合食管切除术后食管鳞状细胞癌患者的病理完全缓解率和生存率方面的作用

阅读:1

Abstract

IntroductionThis study sought to develop a predictive model using CT-based habitat radiomics to forecast pathological complete response (pCR) and progression-free survival (PFS) in esophageal squamous cell carcinoma (ESCC) patients receiving standardized neoadjuvant chemoradiotherapy (nCRT) followed by curative surgery.MethodsWe retrospectively analyzed baseline CT imaging data from 228 ESCC patients in a prospective cohort database. Patients were randomly divided into training and validation sets (7:3 ratio). Whole-tumor and habitat-derived radiomic features were extracted from pretreatment CT scans. For pCR prediction, habitat signatures were developed using Logistic Regression (LR), RandomForest (RF), and XGBoost models, optimized via grid search. PFS prediction employed Cox proportional hazards modeling with selected features. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), Hosmer-Lemeshow calibration curves, and decision curve analysis.ResultsThe habitat models retained 10 features for pCR prediction and 12 for PFS prediction. For pCR, the habitat-derived RF model demonstrated superior performance (training AUC: 0.821; validation AUC: 0.826), outperforming both other habitat models and the whole-tumor radiomics model (training AUC: 0.645). Similarly, the habitat-based RF model for PFS achieved higher AUCs (training: 0.759, 95% CI: 0.627-0.889; validation: 0.810, 95% CI: 0.653-0.966) compared to whole-tumor radiomics (training: 0.623; validation: 0.519).ConclusionOur analyses indicated a trend where habitat radiomics might outperform whole-tumor radiomics in predicting pCR and PFS for resectable ESCC after nCRT. While this merits further investigation, current evidence is insufficient to confirm its clinical utility for personalized treatment guidance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。